Delayed Onset and Reduced Cognitive Deficits through Pre-Conditioning with 3-Nitropropionic Acid is Dependent on Sex and CAG Repeat Length in the R6/2 Mouse Model of Huntington’s Disease
Restricted accessResearch articleFirst published online 2016
Delayed Onset and Reduced Cognitive Deficits through Pre-Conditioning with 3-Nitropropionic Acid is Dependent on Sex and CAG Repeat Length in the R6/2 Mouse Model of Huntington’s Disease
Background: Impairments in energy metabolism are implicated in Huntington’s disease (HD) pathogenesis. Reduced levels of the mitochondrial enzyme succinate dehydrogenase (SDH), the main element of complex II, are observed post mortem in the brains of HD patients, and energy metabolism defects have been identified in both presymptomatic and symptomatic HD patients.
Objective: Chemical preconditioning with 3-nitropropionic acid (3-NP), an irreversible inhibitor of SDH, has been shown to increase tolerance against experimental hypoxia in both heart and brain. Here we studied the effect of chronic preconditioning in the R6/2 mouse model of HD using mice carrying CAG repeat lengths of either 250 or 400 repeats. Both are transgenic fragment models, with 250CAG mice having a more rapid disease progression than 400CAG mice.
Methods: Low doses of 3-NP (24 mg/kg) were administered via the drinking water and the effect on phenotype progression and cognition function assessed.
Results: After 3-NP treatment there were significant improvements in all aspects of the behavioural phenotype, apart from body weight, with timing and magnitude of improvements dependent on both CAG repeat length and sex. Specifically, a delay in the deterioration of general health (as shown by delayed onset of glycosuria and increased survival) was seen in both male and female 400CAG mice and in female 250CAG mice and was consistent with improved appearance of 3-NP treated R6/2 mice. Male 250CAG mice showed improvements but these were short term, and 3-NP treatment eventually had deleterious effects on their survival rate. When cognitive performance of 250CAG mice was assessed using a two-choice discrimination touchscreen task, we found that female mice showed significant improvements.
Discussion: Together, our results support the idea that energy metabolism contributes to the pathogenesis of HD, and suggest that improving energy deficits might be a therapeutically useful target.
A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. The Huntington’s Disease Collaborative Research Group. Cell. 1993;72:971–83.
2.
BatesG, HarperP, JonesL. Huntington’s disease. New York: Oxford University Press. 2002;3–27.
3.
GraftonST, MazziottaJC, PahlJJ, St George-HyslopP, HainesJL, GusellaJ, HoffmanJM, BaxterLR, PhelpsME. Serial changes of cerebral glucose metabolism and caudate size in persons at risk for Huntington’s disease. Arch Neurol. 1992;49(11):1161–7.
4.
KuwertT, LangeHW, BoeckerH, TitzH, HerzogH, AulichA, et al. Striatal glucose consumption in chorea-free subjects at risk of Huntington’s disease. J Neurol. 1993;241(1):31–6.
5.
JenkinsBG, KoroshetzWJ, BealMF, RosenBR. Evidence for impairment of energy metabolism in vivo in Huntington’s disease using localized 1H NMR spectroscopy. Neurology. 1993;43(12):2689–95.
6.
BrowneSE, BowlingAC, MacgarveyU, BaikMJ, BergerSC, MuquitMMK, et al. Oxidative damage and metabolic dysfunction in Huntington’s disease: Selective vulnerability of the basal ganglia. Ann Neurol. 1997;41(5):646–53.
7.
SanbergPR, FibigerHC, MarkRF. Body weight and dietary factors in Huntington’s disease patients compared with matched controls. Med J Aust. 1981;1(8):407–9.
8.
MoralesLM, EstévezJ, SuárezH, VillalobosR, Chacín de BonillaL, BonillaE. Nutritional evaluation of Huntington disease patients. Am J Clin Nutr. 1989;50(1):145–50.
9.
CarterRJ, LioneLA, HumbyT, MangiariniL, MahalA, BatesGP, et al. Characterization of progressive motor deficits in mice transgenic for the human Huntington’s disease mutation. J Neurosci. 1999;19(8):3248–57.
10.
LiJY, PopovicN, BrundinP. The use of the R6 transgenic mouse models of Huntington’s disease in attempts to develop novel therapeutic strategies. NeuroRx. 2005;2(3):447–64.
11.
van der BurgJM, BacosMK, WoodNI, LindqvistA, WierupN, WoodmanB, et al. Increased metabolism in the R6/2 mouse model of Huntington’s disease. Neurobiol Dis. 2008;29(1):41–51.
12.
MortonAJ, GlynnD, LeavensW, ZhengZ, FaullRL, SkepperJN, et al. Paradoxical delay in the onset of disease caused by super-long CAG repeat expansions in R6/2 mice. Neurobiol Dis. 2009;33(3):331–41.
13.
TrounceI, ByrneE, MarzukiS. Decline in skeletal muscle mitochondrial respiratory chain function: Possible factor in ageing. Lancet. 1989;1:637–9.
14.
YenTC, ChenYS, KingKL, YehSH, WeiYH. Liver mitochondrial respiratory functions decline with age. Biochem Biophys Res Commun. 1989;165:944–1003.
15.
BealMF. Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses?Ann Neurol. 1992;31(2):119–30.
16.
BealMF, BrouilletE, JenkinsBG, FerranteRJ, KowallNW, MillerJM, et al. Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J Neurosci. 1993;13:4181–92.
17.
JenkinsBG, RosasHD, ChenYC, MakabeT, MyersR, MacDonaldM, et al. 1H NMR spectroscopy studies of Huntington’s disease: Correlations with CAG repeat numbers. Neurology. 1998;50(5):1357–65.
18.
CoyleJT, SchwarczR. Lesions of striatal neurons with kainic acid provides a model for Huntington’s chorea. Nature. 1976;263:244–6.
19.
McGeerEG, McGeerPL. Duplication of biochemical changes of Huntington’s chorea by intrastriatal injections of glutamic and kainic acids. Nature. 1976;263(5577):517–9.
20.
BealMF, KowallNW, EllisonDW, MazurekMF, SwartzKJ, MartinJB. Replication of the neurochemical characteristics of Huntington’s disease by quinolinic acid. Nature. 1986;321:168–71.
21.
DiFigliaM. Excitotoxic injury of the neostriatum: A model for Huntington’s disease. Trends Neurosci. 1990;13(7):286–9.
22.
CoyleJT, PuttfarckenP. Oxidative stress, glutamate, and neurodegenerative disorders. Science. 1993;262:689–95.
23.
RaymondLA. Excitotoxicity in Huntington disease. Clin Neurosci Res. 2003;3:121–8.
24.
AnithaM, NandhuMS, AnjuTR, JesP, PauloseCS. Targeting glutamate mediated excitotoxicity in Huntington’s disease: Neural progenitors and partial glutamate antagonist— memantine. Med Hypotheses. 2011;76:138–40.
25.
FernandesHB, RaymondLA. NMDA receptors and Huntington’s disease. Biology of the NMDA Receptor. CRC Press; 2009;Chapter 2.
26.
MassieuL, Del RíoP, MontielT. Neurotoxicity of glutamate uptake inhibition in vivo: Correlation with succinate dehydrogenase activity and prevention by energy substrates. Neuroscience. 2001;106:669–77.
27.
Del RioP, MontielT, ChagoyaV, MassieuL. Exacerbation of excitotoxic neuronal death induced during mitochondrial inhibition in vivo: Relation to energy imbalance or ATP depletion?Neuroscience. 2007;146:1561–70.
28.
MortonAJ, LeavensW. Mice transgenic for the human Huntington’s disease mutation have reduced sensitivity to kainic acid toxicity. Brain Res Bull. 2000;52(1):51–9.
29.
Pérez-de la CruzV, SantamaríaA. Integrative hypothesis for Huntington’s disease: A brief review of experimental evidence. Physiol Res. 2007;56:513–26.
30.
ButterworthJ, YatesCM, ReynoldsGP. Distribution of phosphate activated glutaminase, succinic dehydrogenase, pyruvate dehydrogenase and gamma-glutamyl transpeptidase in post mortem brain from Huntington’s disease and agonal cases. J Neurol Sci. 1985;67:161–71.
31.
ZabelC, MaoL, WoodmanB, RoheM, WackerMA, KlareY, et al. A large number of protein expression changes occur early in life and precede phenotype onset in a mouse model for huntington disease. Mol Cell Proteomics. 2009;8:720–34.
AlstonTA, MelaL, BrightHJ. 3-Nitropropionate, the toxic substance of Indigofera, is a suicide inactivator of succinate dehydrogenase. Proc Natl Acad Sci U S A. 1997;74(9):3767–71.
34.
ColesCJ, EdmondsonDE, SingerTP. Inactivation of succinate dehydrogenase by 3-nitropropionate. J Biol Chem. 1979;254(12):5161–7.
35.
BrouilletEP, JenkinsBG, HymanBT, FerranteRJ, KowallNW, SrivastavaR, et al. Age-dependent vulnerability of the striatum to the mitochondrial toxin 3-nitropropionic acid. J Neurochem. 1993;60:356–9.
36.
BrouilletE, HantrayeP, FerranteRJ, DolanR, Leroy-WilligA, KowallNW, et al. Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates. Proc Natl Acad Sci U S A. 1995;92:7105–9.
BorlonganCV, KoutouzisTK, SanbergPR. 3-Nitropropionic acid animal model and Huntington’s disease. Neurosci Biobehav Rev. 1997;21(3):289–93.
39.
BogdanovMB, FerranteRJ, KuemmerleS, KlivenyiP, BealMF. Increased vulnerability to 3-nitropropionic acid in an animal model of Huntington’s disease. J Neurochem. 1998;71:2642–4.
40.
HickeyMA, MortonAJ. Mice transgenic for the Huntington’s disease mutation are resistant to chronic 3-nitropropionic acid-induced striatal toxicity. J Neurochem. 2000;75(5):2163–71.
41.
TsaiBM, WangM, MarchKL, TurrentineMW, BrownJW, MeldrumDR. Preconditioning: Evolution of basic mechanisms to potential therapeutic strategies. Shock. 2004;21(3):195–209.
42.
JanoffA. Alterations in lysosomes (intracellular enzymes) during shock: Effects of preconditioning (tolerance) and protective drugs. Int Anesth Clin. 1964;2:251–9.
43.
RiepeMW, KasischkeK, GerickeCA, LöweA, HellwegR. Increase of hypoxic tolerance in rat hippocampal slices following 3-nitropropionic acid is not mediated by endogenous nerve growth factor. Neurosci Lett. 1996;211(1):9–12.
44.
RiepeMW, LudolphAC. Chemical preconditioning: A cytoprotective strategy. Mol Cell Biochem. 1997;174:249–54.
45.
GarnierP, BertrandN, DemougeotC, Prigent-TessierA, MarieC, BeleyA. Chemical preconditioning with 3-nitropropionic acid: Lack of induction of neuronal tolerance in gerbil hippocampus subjected to transient forebrain ischemia. Brain Res Bull. 2002;1:33–9.
46.
TuranN, CsonkaC, CsontT, GiriczZ, FodorG, BencsikP, et al. The role of peroxynitrite in chemical preconditioning with 3-nitropropionic acid in rat hearts. Cardiovasc Res. 2006;70(2):384–90.
47.
TuranNN, BasgutB, AyparE, ArkM, IskitAB, CakiciI. Chemical preconditioning effect of 3-nitropropionic acid in anesthetized rat heart. Life Sci. 2008;82(17-18):928–33.
48.
Van WinkleDM, ThorntonJD, DowneyDM, DowneyJM. The natural history of preconditioning: Cardioprotection depends on duration of transient ischemia and time to subsequent ischemia. Coron Artery Dis. 1991;2:613–9.
49.
JenkinsDP, PugsleyWB, YellonDM. Ischaemic preconditioning in a model of global ischaemia: Infarct size limitation, but no reduction of stunning. J Mol Cell Cardiol. 1995;27(8):1623–32.
50.
YangXM, BaxterGF, HeadsRJ, YellonDM, DowneyJM, CohenMV. Infarct limitation of the second window of protection in conscious rabbit model. Cardiovasc Res. 1996;31:777–83.
51.
HanssonO, PetersenA, LeistM, NicoteraP, CastilhoRF, BrundinP. Mice expressing a Huntington’s disease mutation are resistant to quinolinic acid-induced striatal excitotoxicity. Proc Natl Acad Sci U S A. 1999;96:8727–32.
52.
CarterRJ, HuntMA, MortonAJ. Environmental stimulation increases survival in mice transgenic for exon 1 of the Huntington’s disease gene. Mov Disord. 2000;15:925–37.
53.
GlynnD, BortnickRA, MortonAJ. Complexin II is essential for normal neurological function in mice. Hum Mol Genet. 2003;12(19):2431–48.
54.
MortonAJ, SkillingsE, BusseyTJ, SaksidaLM. Measuring cognitive deficits in disabled mice using an automated interactive touchscreen system. Nat Methods. 2006;3(10):767.
55.
HuntMJ, MortonAJ. Atypical diabetes associated with inclusion formation in the R6/2 mouse model of Huntington’s disease is not improved by treatment with hypoglycaemic agents. Exp Brain Res. 2005;166(2):220–9.
56.
BenchouaA, TrioulierY, ZalaD, GaillardM, LefortN, DufourN, et al. Involvement of mitochondrial complex II defects in neuronal death produced by N-terminus fragment of mutated huntingtin. Mol Biol Cell. 2006;17(4):1652–63.
57.
ReynoldsDS, CarterRJ, MortonAJ. Dopamine modulates the susceptibility of striatal neurons to 3-nitropropionic acid in the rat model of Huntington’s disease. J Neurosci. 1998;18(23):10116–27.
MihmMJ, AmannDM, SchanbacherBL, AltschuldRA, BauerJA, HoytKR. Cardiac dysfunction in the R6/2 mouse model of Huntington’s disease. Neurobiol Dis. 2007;25:297–308.
60.
WoodNI, SawiakSJ, BuonincontriG, NiuY, KaneAD, CarpenterTA, et al. Direct evidence of progressive cardiac dysfunction in a transgenic mouse model of Huntington’s disease. J Huntingtons Dis. 2012;1:57–64.
61.
BuonincontriG, WoodNI, PuttickSG, WardAO, CarpenterTA, SawiakSJ, et al. Right ventricular dysfunction in the R6/2 transgenic mouse model of Huntington’s disease is unmasked by dobutamine. J Huntingtons Dis. 2014;3(1):25–32.
62.
GabrielsonKL, HogueBA, BohrVA, CardounelAJ, NakajimaW, KoflerJ, et al. Mitochondrial toxin 3-nitropropionic acid induces cardiac and neurotoxicity differentially in mice. Am J Pathol. 2001;159:1507–20.
63.
HuZ, YangY, ZhangK, SunZ. Chemical preconditioning by 3-nitropropionic acid reduces ischemia-reperfusion injury in rat heart. J Huazong Univ Sci Technolog Med Sci. 2005;25:439–41.
64.
BasgutB, AyparE, BasgutE, Okhan AklnK, KilicN, CakiciI. The mechanism of the late preconditioning effect of 3-nitropropionic acid. Arch Pharm Res. 2008;31(10):1257–63.
65.
WoodNI, CartaV, MildeS, SkillingsEA, McAllisterCJ, AngYL, et al. Responses to environmental enrichment differ with sex and genotype in a transgenic mouse model of Huntington’s disease. PLoS One. 2010;5:e9077.
66.
WoodNI, GlynnD, MortonAJ. “Brain training” improves cognitive performance and survival in a transgenic mouse model of Huntington’s disease. Neurobiol. Dis. 2011;42(3):427–37.
67.
NishinoH, NakajimaK, KumazakiM, FukudaA, MuramatsuK, DeshpandeSB, et al. Estrogen protects against while testosterone exacerbates vulnerability of the lateral striatal artery to chemical hypoxia by 3-nitropropionic acid. Neurosci Res. 1998;30(4):303–12.
68.
MogamiM, HidaH, HayashiY, KohriK, KodamaY, Gyun JungC, et al. Estrogen blocks 3-nitropropionic acid-induced Ca2+i increase and cell damage in cultured rat cerebral endothelial cells. Brain Res. 2002;956(1):116–25.
69.
PapalexiE, PerssonA, BjörkqvistM, PetersénA, WoodmanB, BatesGP, et al. Reduction of GnRH and infertility in the R6/2 mouse model of Huntington’s disease. Eur J Neurosci. 2005;22(6):1541–6.
70.
LioneLA, CarterRJ, HuntMJ, BatesGP, MortonAJ, DunnettSB. Selective discrimination learning impairments in mice expressing the human Huntington’s disease mutation. J Neurosci. 1999;19(23):10428–37.
71.
MangiariniL, SathasivamK, SellerM, CozensB, HarperA, HetheringtonC, et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell. 1996;87:493–506.
72.
StackEC, KubilusJK, SmithK, CormierK, Del SignoreSJ, GuelinE, et al. Chronology of behavioral symptoms and neuropathological sequela in R6/2 Huntington’s disease transgenic mice. J Comp Neurol. 2005;490:354–70.
73.
HeF, ZhangS, QianF, ZhangC. Delayed dystonia with striatal CT lucencies induced by a mycotoxin (3-nitropropionic acid). Neurology. 1995;45:2178–83.
